| Title: |
Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study. |
| Authors: |
Martínez Castelao, Alberto; Cases Amenós, A. (Aleix); Torre Carballada, Alberto; Torralba Iranzo, Alberto; Bronsoms, Josep; Vallès Prats, Martí; Torán, Daniel; Masso Jimenez, Elisabet; Investigators of the ACERCA Study Group |
| Source: |
Articles publicats en revistes (Medicina) |
| Publisher Information: |
Elsevier España |
| Publication Year: |
2015 |
| Collection: |
Dipòsit Digital de la Universitat de Barcelona |
| Subject Terms: |
Anèmia; Insuficiència renal crònica; Eritropoesi; Eritropoetina; Hemoglobina; Assaigs clínics; Anemia; Chronic renal failure; Erythropoiesis; Erythropoietin; Hemoglobin; Clinical trials |
| Description: |
BACKGROUND AND OBJECTIVE: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13 g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of this statement in the anemia management of chronic kidney disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain. METHODS: This was an observational and cross-sectional study carried out in CKD patients not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous ESA to another ESAs (converted) since January 2011. RESULTS: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve patients and 7.9% of those converted had Hb levels >13 g/dL. Hb levels were similar across subgroups of patients, regardless of the presence of significant comorbidities. CONCLUSIONS: Anemia management in CKD patients treated with ESAs by Spanish nephrologists seems to be aimed at preventing Hb levels |
| Document Type: |
article in journal/newspaper |
| File Description: |
10 p.; application/pdf |
| Language: |
English |
| Relation: |
Reproducció del document publicat a: https://doi.org/10.1016/j.nefro.2015.05.018; Nefrología, 2015, vol. 35, num. 2, p. 179-188; https://doi.org/10.1016/j.nefro.2015.05.018; https://hdl.handle.net/2445/105582; 653759 |
| Availability: |
https://hdl.handle.net/2445/105582 |
| Rights: |
cc-by-nc-nd (c) Sociedad Española de Nefrología, 2015 ; http://creativecommons.org/licenses/by-nc-nd/3.0/es ; info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.E9910D3A |
| Database: |
BASE |